Natrijev Oksibat Accord (Sodium Oxybate)

Sodium oxybate, the active ingredient in Natrijev Oksibat Accord, is a gamma‑hydroxybutyrate (GHB) class medication presented as an oral solution for oral use. It is used to treat narcolepsy with cataplexy and excessive daytime sleepiness in adults. GNH USA supplies Natrijev Oksibat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium oxybate acts on the central nervous system to address sleep‑related disorders, particularly narcolepsy.

Narcolepsy with cataplexy: reduces the frequency and severity of cataplexy episodes. Excessive daytime sleepiness in narcolepsy: improves wakefulness and alertness during the day. Sleep fragmentation in narcolepsy: helps consolidate nighttime sleep and normalize sleep architecture.

Sodium oxybate may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Headache - Dizziness or light‑headedness - Enuresis (nighttime urination) - Anxiety or nervousness - Insomnia or disturbed sleep

Serious or Rare Side Effects: - Respiratory depression, especially when combined with other CNS depressants - Severe hypotension or cardiovascular instability - Seizures or convulsions - Allergic reactions such as rash, angioedema, or anaphylaxis - Potential for misuse or dependence due to GHB properties

When prescribing sodium oxybate, clinicians should consider several safety measures.

Dose titration: follow the prescriber's individualized dosing schedule. Alcohol avoidance: patients must not consume alcohol while on therapy. Driving and operating machinery: avoid until the individual's response is known. Renal impairment: assess kidney function and adjust if necessary. History of depression or suicidal thoughts: monitor mental health closely. Store at ambient temperature: keep in the original container, protect from moisture and light.

Sodium oxybate can interact with other substances that depress the central nervous system.

Major Interactions (Avoid): - Alcohol: additive CNS depression and increased risk of respiratory depression. - Opioids: heightened risk of severe respiratory depression. - Benzodiazepines or other GHB‑containing products: synergistic sedation and respiratory effects.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs, SNRIs): may increase sedation. - Antihistamines: can enhance dizziness and drowsiness. - Antihypertensives: possible additive hypotensive effect.